A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.
Public ClinicalTrials.gov record NCT00267254. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.
Study identification
- NCT ID
- NCT00267254
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 640 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2006 (Type not available)
- Primary completion
- Not listed
- Completion
- Aug 2006 (Actual)
- Last update posted
- Nov 21, 2007
2006
United States locations
- U.S. sites
- 49
- U.S. states
- 26
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | — | — |
| Pfizer Investigational Site | Mobile | Alabama | — | — |
| Pfizer Investigational Site | Mesa | Arizona | — | — |
| Pfizer Investigational Site | Phoenix | Arizona | — | — |
| Pfizer Investigational Site | Tempe | Arizona | — | — |
| Pfizer Investigational Site | Little Rock | Arkansas | — | — |
| Pfizer Investigational Site | Los Angeles | California | — | — |
| Pfizer Investigational Site | San Diego | California | — | — |
| Pfizer Investigational Site | Santa Rosa | California | — | — |
| Pfizer Investigational Site | Boynton Beach | Florida | — | — |
| Pfizer Investigational Site | Melbourne | Florida | — | — |
| Pfizer Investigational Site | Merritt Island | Florida | — | — |
| Pfizer Investigational Site | Palm Bay | Florida | — | — |
| Pfizer Investigational Site | Safety Harbor | Florida | — | — |
| Pfizer Investigational Site | Tampa | Florida | — | — |
| Pfizer Investigational Site | Chicago | Illinois | — | — |
| Pfizer Investigational Site | Newton | Kansas | — | — |
| Pfizer Investigational Site | Topeka | Kansas | — | — |
| Pfizer Investigational Site | Wichita | Kansas | — | — |
| Pfizer Investigational Site | Madisonville | Kentucky | — | — |
| Pfizer Investigational Site | Boston | Massachusetts | — | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | — | — |
| Pfizer Investigational Site | Canton | Michigan | — | — |
| Pfizer Investigational Site | Portage | Michigan | — | — |
| Pfizer Investigational Site | Troy | Michigan | — | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | — | — |
| Pfizer Investigational Site | Kansas City | Missouri | — | — |
| Pfizer Investigational Site | St Louis | Missouri | — | — |
| Pfizer Investigational Site | Butte | Montana | — | — |
| Pfizer Investigational Site | Lincoln | Nebraska | — | — |
| Pfizer Investigational Site | Las Vegas | Nevada | — | — |
| Pfizer Investigational Site | Concord | New Hampshire | — | — |
| Pfizer Investigational Site | Trenton | New Jersey | — | — |
| Pfizer Investigational Site | Cooperstown | New York | — | — |
| Pfizer Investigational Site | East Syracuse | New York | — | — |
| Pfizer Investigational Site | Rochester | New York | — | — |
| Pfizer Investigational Site | Charlotte | North Carolina | — | — |
| Pfizer Investigational Site | Cincinnati | Ohio | — | — |
| Pfizer Investigational Site | Clinton | South Carolina | — | — |
| Pfizer Investigational Site | Cordova | Tennessee | — | — |
| Pfizer Investigational Site | Memphis | Tennessee | — | — |
| Pfizer Investigational Site | Milan | Tennessee | — | — |
| Pfizer Investigational Site | Dallas | Texas | — | — |
| Pfizer Investigational Site | Fort Worth | Texas | — | — |
| Pfizer Investigational Site | San Antonio | Texas | — | — |
| Pfizer Investigational Site | Payson | Utah | — | — |
| Pfizer Investigational Site | Salt Lake City | Utah | — | — |
| Pfizer Investigational Site | Norfolk | Virginia | — | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00267254, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2007 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00267254 live on ClinicalTrials.gov.